Results per Page:
New drug regimen prevents both chronic and acute graft-versus-host disease
From Dr. Masumi Ueda Oshima and colleagues, Clinical Research Division
Viruses are linked to lung disease in hematopoietic cell transplant recipients
From the Boeckh Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Novel drug regimen reduces risks of graft-versus-host disease
From the Hill Group, Translational Science and Therapeutics Division in collaboration with Alfred Health and Monash University
Donor factors influence success of fecal microbiota transplant
From the Rashidi Group, Pathogen Associated Malignancies Program of the Cancer Consortium and Clinical Research Division
Decisions, decisions: factors that impact HCT outcomes in AML
From the Walter Group, Translational Sciences and Therapeutics Division
Revaccination beliefs and behaviors in transplant survivors
From the UW School of Nursing in collaboration with the Long-Term Follow-Up Program, Clinical Research Division
Mutations remain one-in-a-million after HCT
From the Storb Group, Clinical Research Division
A charming model: new tool evaluates risk of transplant for older patients
Seven values are evaluated to predict outcomes
A new era of COVID-19 brings new outlooks for cellular therapy recipients
From the Liu Group, Vaccine and Infectious Disease Division
Graft-versus-host disease outcomes improving for all Fred Hutch patients
From the Long-Term Follow-Up Research Group, Clinical Research Division
Age or HLA? Helping doctors pick the best blood stem cell donors for their patients
From Drs. Rohtesh Mehta and Stephanie Lee, Clinical Research Division
Gut microbes dictate donor T cell expansion and graft-versus-host disease risk after stem cell transplantation
From the Hill Lab, Translational Science and Therapeutics Division
Life after stem cell transplant: Finding ways to improve survivors’ transition back to work.
From Dr. Rachel Salit and colleagues, Clinical Research Division
Safety and feasibility approved for new therapy to treat relapsed hematologic malignancies
From the Bleakley Lab, Translational Science & Therapeutics Division
Secret to tamping down GVHD may lie in microbial genetics
Preclinical bone marrow transplant study shows donor immune cells that target recipient microbiome can influence GVHD severity
COVID-19 prior to cellular therapy is likely not a cause for alarm.
From the Hill Group, Clinical Research Division and Vaccine and Infectious Disease Division
Microbial cell-free DNA may help predict transplantation outcomes
From the Markey Lab, Translational Science and Therapeutics Division
HLA haplotype allelic variations can influence leukemia recurrence after blood stem cell transplantation
From the Petersdorf Group, Translational Science and Therapeutics Division
Bone marrow transplant increases risk of cardiovascular disease and developing insulin resistance.
From Drs. Tyler Ketterl, Scott Baker and colleagues, Clinical Research Division